Abstract
Background
Nearly 1 million new episodes of herpes zoster (HZ) occur annually in the US, yet little is known about the medical resource utilization (RU) and costs associated with HZ and its complications.
Objective
To describe the medical RU and cost burden of HZ in the first 90 days and the first year after diagnosis from the health insurer perspective and to stratify this burden for patients diagnosed with post-herpetic neuralgia (PHN) and those who are immunocompromised. In addition, this study explores costs from the societal perspective as a result of work loss in the first year after diagnosis.
Methods
The medical RU and cost data were obtained from the MarketScan® Research Database for the years 1998–2003. This database contains inpatient, outpatient and prescription drug data for approximately 14 million individuals of all ages, covered under a variety of fee-for-service and capitated provider reimbursement arrangements, including those with Medicare and private insurance. The work loss estimates were based on the MarketScan® Health and Productivity Management Database.
Claims for services incurred between 1 January 1998 and 31 December 2003 were screened to identify a cohort of HZ patients based on the presence of at least one International Classification of Diseases, 9th Revision (ICD-9) diagnosis code 053.xx. Each patient was assigned an index date based on the earliest observed occurrence of an HZ diagnosis. A cohort of PHN patients was identified as a subset of the HZ cohort with ICD-9 codes 053.12, 053.13, 053.19 or 729.2x in the period of 90 days to 12 months after the index date.
Multivariable regression was used to compare HZ cases with matched controls after adjusting for demographic characteristics, insurance status, co-morbidities and medical expenditure in the 6 months prior to diagnosis for each of the endpoints. Separate regression models were developed, in which age and immune status were stratified. All costs were adjusted to March 2008 values using the medical care component of the Consumer Price Index.
Results
The average per patient cost of all HZ cases was $US605 in the first 90 days after diagnosis and $US1052 at 1 year. For the subset with PHN, the average per patient cost of HZ at 1 year was $US3815. For the subset with an immunocompromising condition, the average HZ cost at 1 year was $US1745. The majority of the costs were the result of outpatient visits and prescription drugs. The subset of HZ cases that had both absence hour and short-term disability (STD) records available had 26.5 absence hours and 2.9 STD days. Healthcare utilization, medical care costs and work loss all increased with age for all HZ cases.
Conclusions
Based on the results from the present study, the direct medical cost burden of HZ in the US is high, exceeding $US1000 per HZ patient. This direct medical cost may be nearly twice as high in immunocompromised patients and four times as high in the subset of HZ cases with PHN. The direct medical cost burden of HZ may exceed $US1 billion annually in the US. The majority of medical RU and cost burden is incurred by the elderly. Although many people with HZ may no longer be in the workforce, HZ does contribute to lost work time.
Similar content being viewed by others
References
Gnann Jr JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002; 347 (5): 340–6
Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20 (8): 748–53
Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995; 155 (15): 1605–9
Smith JB, Fenske NA. Herpes zoster and internal malignancy. South Med J 1995; 88 (11): 1089–92
Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (2): 370–5
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20
Ragozzino MW, Melton III LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61 (5): 310–6
Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36 (7): 877–82
Lydick E, Epstein RS, Himmelberger D, et al. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 1995; 45 (12 Suppl. 8) S52–3
Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008; 26 (3): 235–49
Dworkin RH, Portenoy RK. Proposed classification of herpes-zoster pain [letter]. Lancet 1994; 343 (8913): 1648
Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics 2007; 25 (2): 155–69
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352 (22): 2271–84
Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22 (2): 341–7
Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 2000; 20 (1): 50–8
Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94 (2): 215–24
Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280 (21): 1837–42
Sang CN, Booher S, Gilron I, et al. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96 (5): 1053–61
Watson CPN, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51 (4): 1166–71
Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50 (6): 1837–41
Dworkin RH, Carrington D, Cunningham A, et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Research 1997; 33 (2): 73–85
Dworkin RH, Corbin AE, Young JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60 (8): 1274–83
Harke H, Gretenkort P, Ladleif HU, et al. Spinal cord stimulation in postherpetic neuralgia and in acute herpes zoster pain. Anesth and Analg 2002; 94 (3): 694–700
Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109 (1–2): 26–35
Watson CPN, Watt VR, Chipman M, et al. The prognosis with postherpetic neuralgia. Pain 1991; 46 (2): 195–9
Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3 (4): 335–42
Dworkin RH, White R, O’Connor AB, et al. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007; 55 (8): 1168–75
United States Department of Labor. Bureau of Labor Statistics. CPI detailed report: data for March 2008 [online]. Available from URL: http://www.bls.gov/cpi/cpid0803.pdf [Accessed 2008 Sep 2]
Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidem 1993; 46 (10): 1075–9
Ghali WA, Hall RE, Rosen AK, et al. Searching for an improved clinical comorbidity index for use with ICD-9-CM administrative data. J Clin Epidem 1996; 49 (3): 273–8
Gnann Jr JW. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186 Suppl. 1: S91–8
Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321 (7264): 794–6
Jung BF, Johnson RW, Griffin DR, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62 (9): 1545–51
Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70 Suppl. 1: S24–30
United States Department of Labor. Bureau of Labor Statistics. May 2008 national wage estimates [online]. Available from URL: http://www.bls.gov/oes/2008/may/oes_nat.htm#b00-0000 [Accessed 2009 Aug 3]
Helgason S, Sigurdsson JA, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12–6
Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24 (9): 1308–14
Mullooly JP, Riedlinger K, Chun C, et al. Incidence of herpes zoster, 1997–2002. Epidemiol Infect 2005; 133 (2): 245–53
Centers for Disease Control and Prevention. National Center for Health Statistics. Health insurance coverage [online]. Available from URL: http://www.cdc.gov/nchs/fastats/hinsure.htm [Accessed 2008 Sep 2]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
White, R.R., Lenhart, G., Singhal, P.K. et al. Incremental 1-Year Medical Resource Utilization and Costs for Patients with Herpes Zoster from a Set of US Health Plans. Pharmacoeconomics 27, 781–792 (2009). https://doi.org/10.2165/11317560-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11317560-000000000-00000